Objective: The objective of this study was to assess long-term outcome after thoracic endovascular aortic repair (TEVAR) for thoracic aortic aneurysm (TAA).
Thoracic endovascular aortic repair (TEVAR) was first performed by Volodos in 1987 in a patient with a posttraumatic thoracic aneurysm. 1 This minimally invasive technique was soon observed to be associated with lower perioperative morbidity and mortality than in open surgical repair of the descending aorta. It was initially proposed as an alternative to open repair especially in the elderly population with significant comorbidities. 2, 3 During the following decades, TEVAR has grown to become the treatment of choice in the setting of descending aortic aneurysm, complicated type B dissection, and traumatic transection. 4 TEVAR offers an opportunity to treat a higher proportion of patients with thoracic aortic aneurysm (TAA). This is especially true for patients admitted for thoracic aortic rupture, an area in which TEVAR has expanded the possibility of offering repair to many patients who previously were regarded as unfit for surgery. 5 Despite the widespread use of TEVAR for treatment of patients with TAA, the scientific basis for this therapy is scarce. Retrospective registry studies have indicated favorable perioperative outcome of TEVAR in treatment of TAA, but the long-term outcome is less well characterized. 5, 6 In national registry-based studies in the United States and the United Kingdom, the long-term outcome of TEVAR has been worse than that after open repair. 5, 7 The aim of this study was to assess the short-and long-term outcome of TEVAR for intact TAA (iTAA) and ruptured TAA (rTAA) at a tertiary referral center. The cause of late death was specifically addressed to analyze how effectively TEVAR for TAA prevents aortic death. A secondary aim was to evaluate predictors of mortality.
METHODS
All patients (N ¼ 304) who underwent an attempt at TEVAR at Uppsala University Hospital during the 15-year period of December 1999 through December 2014 were identified by way of the prospective local hospital registries and the Swedish National Vascular Registry (Swedvasc). All patients operated on with the indication of intact or ruptured degenerative TAA were included in the current study. Aneurysms secondary to chronic dissection and anastomotic pseudoaneurysms were excluded.
Selection of patients and procedure details. The indication for surgical treatment of TAA at the study center was a fusiform aneurysm >6 cm or presence of symptoms (aneurysm rupture or chest or back pain suspected of being related to the aneurysm). The diameter threshold was lowered for saccular aneurysms. Before invasive treatment, all patients were assessed, and the cases were discussed at a multidisciplinary conference involving cardiothoracic surgeons, vascular surgeons, and interventional radiologists. Stent graft treatment for TAA was initiated in 1999 at the study center. During the course of the study, TEVAR gradually replaced open surgical repair as the first-choice strategy for treatment of TAA for all eligible patients without connective tissue disease.
Spinal drainage was inserted in elective cases in which >20 cm of aortic coverage was planned. Supra-aortic revascularization was performed routinely before TEVAR with bypass if the proximal landing zone was planned to be proximal to the left common carotid artery. Left subclavian artery revascularization was performed selectively. The procedure was performed in a hybrid operating room with the patient under general anesthesia. Femoral access was achieved with cutdown or percutaneous puncture. Femoral closure was performed with arteriorrhaphy, closure device, or fascia suture. Post-TEVAR follow-up consisted of routine computed tomography angiography with arterial-phase contrast imaging at 1 month, at 1 year, and annually thereafter. Reintervention was performed in case of presence of type I or type III endoleak, migration, or progression of disease. Stent graft relining, proximal or distal stent graft extension, and embolization of branch vessels were considered aortic reinterventions.
Data collection and analysis. Characteristics of the patients and outcome data were collected from medical records and imaging studies. Preoperative comorbidity data included history of heart disease (myocardial infarction, angina, cardiac revascularization, cardiac failure, or atrial fibrillation), chronic obstructive pulmonary disease, renal failure (creatinine concentration >150 mmol/L or renal replacement therapy), medically treated diabetes mellitus, medically treated hypertension, cerebrovascular disease (ischemic or hemorrhagic stroke), and prior aortic surgery. Operative details and adjunct procedures were registered. Stent graft landing zones were categorized according to the Ishimaru classification. 8 
RESULTS
Patient demographics. In total, 77 patients were included; 49 (64%) were treated for iTAA and 28 (36%) for rTAA. Forty-one (84%) of the intact aneurysms were treated electively and eight (16%) urgently (ie, within 24 hours of presentation). Characteristics of the patients are presented in Table I . Patients treated for rupture were older and had a higher rate of previous cerebrovascular disease but were more seldom smokers. Of the 77 patients, 14 (18%) had undergone previous aortic surgery; of these, 3 had a history of thoracic aortic repair (1 for an ascending aortic aneurysm, 1 for aortic coarctation, and 1 for a descending aortic aneurysm) and 11 had Procedure details. The mean number of stent grafts used was 1.6 in the iTAA group and 1.5 in the rTAA group. The most frequently used stent graft types were Gore TAG (W. L. Gore & Associates, Flagstaff, Ariz; 25 for iTAA, 15 for rTAA) and Cook TX2 (Cook Medical, Bloomington, Ind; 17 for iTAA, 8 for rTAA). The other types used were Medtronic Valiant (Medtronic, Minneapolis, Minn; two for iTAA, one for rTAA), Bolton Relay (Bolton Medical, Sunrise, Fla; one for iTAA, none for rTAA), or combinations of different stent graft types (four for iTAA, two for rTAA).
Spinal drainage and revascularization of supra-aortic vessels, both efforts to decrease the risk of neurologic complications, were the most common adjunct procedures (Table II) . Six patients required supra-aortic vessel stenting (three iTAA patients, three rTAA patients). Five of these were performed because of accidental coverage of the branch vessel during TEVAR with the Gore (four) and Cook (one) thoracic stent grafts. Stenting of the right carotid artery was done because of a stenosis in the artery cranial to a carotid-carotid bypass.
Because of perioperative access vessel rupture, the iliac artery was stented in two cases; in one case, an iliac plug was placed, followed by a femorofemoral crossover bypass. One patient presented with both clinical and radiologic evidence of an aortic rupture and presence of both large thoracic and abdominal aneurysm. This patient was successfully treated with concomitant open abdominal aortic aneurysm repair and TEVAR. In two rTAA cases, an adequate access could not be established, and one of these patients died on the table; the other one died shortly thereafter.
Perioperative outcome. Perioperative survival, complications, and reinterventions are presented in Table III . After iTAA repair, survival was 95.9% (standard error [SE], 2.9%) at 30 days and 91.8% (SE, 4.0%) at 90 days. There were two deaths within 30 days, one from a rupture of the treated aneurysm with presence of endoleak 2 days after TEVAR and one due to a cardiac event. In addition, two patients died within 90 days after the procedure, one in multiple organ failure after TEVAR and one from rupture of a 5-cm abdominal aortic aneurysm. After rTAA repair, survival was 71.4% (SE, 8.7%) at 30 days and decreased to 57.1% (SE, 9.5%) at 90 days. The eight deaths within 30 days were all related to the treated pathologic process. Another three suffered aorta-related deaths during the first 90 days after the procedure: one due to perioperative cerebral infarction; one due to postoperative tetraparesis, anoxic brain damage, and respiratory insufficiency secondary to both hemothorax and shock treatment with large volumes of intravenous fluids; and one due to an aortoesophageal fistula. One patient treated for a ruptured aneurysm became permanently paraplegic and survived. Spinal ischemia was suspected in five other cases (three iTAA cases, two rTAA cases), three in which the patient had a transient one-limb paresis, one with a transient one-limb sensory Because of aberrant anatomy, the right subclavian artery was chosen as the donor instead of the right common carotid artery. loss, and one with ataxia and bladder dysfunction. All these patients were treated with spinal drainage and hemodynamic optimization and recovered fully. Five patients required early aortic reintervention (three iTAA patients, two rTAA patients). A type I endoleak necessitated proximal extension in one case and a distal extension in two cases. Subclavian artery embolization was performed in two cases because of endoleak.
The reason for early postoperative supra-aortic vessel revascularization was an impending occlusion of the left common carotid artery in one case and signs of spinal ischemia in the other case. One patient developed critical lower limb ischemia ultimately leading to amputation. Bowel resection was required in another case, in which a stent graft was implanted for an aneurysm in the distal descending aorta. The patient had a shaggy aorta with aortic thrombus, and the stent graft partially covered the celiac trunk. The superior mesenteric artery was patent at the completion of the procedure. Both periprocedural embolization from the shaggy aorta and hypoperfusion may have contributed to the development of mesenteric ischemia.
Long-term outcome. The mean follow-up time was 83.7 months for iTAA patients and 82.0 months for rTAA patients (P ¼ .853). Late reinterventions are presented in Table IV . Median time to first aortic reintervention was 3.8 months in the iTAA group and 0.3 month in the rTAA group (P ¼ 1.000). The majority of the reinterventions occurred during the first year after repair (Fig 1) . The 5-year reintervention rate was 13.2% after iTAA repair and 17.9% after rTAA repair (P ¼ .682). Stent graft relining was required in one case because of stent graft kinking, dislocation, and type III endoleak. Proximal and distal extensions were made to stop type Ia and type Ib endoleaks, respectively, in two cases and to cover a rupture distal to the previous stent graft in one case. Celiac trunk embolization was performed in another case because of endoleak.
The Kaplan-Meier estimated survival among iTAA patients was 85.7% (SE, 5.0%) at 1 year, 77.0% (SE, 6.1%) at 3 years, and 62.5% (SE, 7.3%) at 5 years (Fig 2) . Among those treated for rTAA, the survival estimate was 39.3% (SE, 9.2%) at 1 year and 27.8% (SE, 8.6%) at 3 years. Only one patient with 5-year follow-up after treatment of rTAA was alive. In octogenarians with rTAA, 30-day survival was 62.5% (SE, 18.3%), 90-day survival was 37.5% (SE, 18.3%), and estimated 1-year survival was 25.0% (SE, 15.3%). Causes of death are listed in Table V ; 21% of the late (>30 days) deaths in the iTAA group and 40% in the rTAA group were aorta related. There were three aorta-related deaths after >90 days among the Spinal cord ischemia 3 (6) 3 (11) .470
Permanent paraplegia 0 (0) 1 (4) .183
Respiratory failure 3 (6) 4 (14) .231
Renal failure 1 (2) 1 (4) .914
Cardiac event 2 (4) 0 (0) .120
Aortic reinterventions
Proximal extension 1 (2) 0 (0) .447
Distal extension 0 (0) 2 (7) .058
Subclavian embolization 2 (4) 0 (0) .279
Other reinterventions
Hemothorax evacuation 0 (0) 3 (11) .019
Exploration of access vessel 2 (4) 0 (0) .279
Evacuation of neck hematoma after revascularization of supra-aortic vessels 1 (2) 0 (0) .447
Supra-aortic vessel revascularization 1 (2) 1 (4) .685
Resection of ischemic bowel 1 (2) 0 (0) .447
Lower limb amputation 0 (0) 1 (4) .183
Thrombin injection of pseudoaneurysm 1 (2) 0 (0) .447
iTAA, Intact thoracic aortic aneurysm; rTAA, ruptured thoracic aortic aneurysm; SE, standard error.
iTAA patients. One patient suffered an aortic dissection with rupture 4 months after TEVAR. This patient had a carotid-carotid-subclavian bypass and TEVAR of a descending aortic aneurysm, originating distal to the brachiocephalic trunk (zone 1) and extending to the celiac trunk. Postoperative computed tomography showed thrombosis of the aneurysm sac without any visible endoleak. The patient developed signs of graft infection in the supra-aortic deviation bypasses 1 month after the primary operation, which was treated with revision of the bypass grafts and antibiotics. Three months later, she died a sudden death; the postmortem examination showed rupture of the descending thoracic aorta distal to the stent graft, with a localized dissection in the aorta at this level. Possible correlation to graft infection could not be verified. A second patient had an aortic rupture 8 months after TEVAR. This patient had TEVAR because of a proximal descending aneurysm before a scoliosis operation. The patient had a history of motor vehicle accident many years earlier, and the aneurysm may thus have been post-traumatic. TEVAR was successful, with the stent graft inserted from distal to the left carotid artery (zone 2) to mid-descending aorta, and the aneurysm sac thrombosed. During the scoliosis operation, her spinal deformation was straightened, resulting in a significant straightening and prolongation of the aorta. One month after the scoliosis operation, the patient presented with massive hemoptysis and rupture of the aorta to an aortobronchial fistula. This fatal event was thought to have been caused by the stretching of the aorta, resulting in a rupture at the distal end of the stent graft. 9 A third patient died 51 months after TEVAR from rupture of a distal aortic aneurysm. This patient with a descending aortic aneurysm had TEVAR from distal to left subclavian artery (zone 3) to distal descending aorta, with thrombosis of the aneurysm sac on follow-up. There was a remaining aneurysm below the treated segment that continued to expand and for which the patient declined surgical treatment. She eventually presented to the hospital with a rupture of this 7-cm aneurysm, verified on postmortem examination. Among the rTAA patients, three suffered aorta-related deaths after >90 days. One died 100 days after TEVAR of rupture of the thoracic aneurysm with perforation to the esophagus. Two other patients had complex aneurysms of the abdominal aorta but were not regarded as candidates for elective surgical repair and died of rupture of the abdominal aorta at 8 months and 17 months, respectively, after TEVAR.
To assess possible changes in outcome over time, the survival outcome after TEVAR was compared for the There was no significant difference in 30-day survival or estimated 5-year survival. Univariable and multivariable predictors of long-term survival were assessed with Cox regression and are presented in Table VI . Aortic rupture was associated with an age-adjusted hazard ratio for death of 4.41 and remained a significant predictor of inferior long-term outcome also when early deaths were excluded from the analysis.
DISCUSSION
In this analysis of long-term outcome after TEVAR for TAA, it was demonstrated to be favorable after iTAA repair. However, the persistent high risk of death within the first years after rTAA repair is important information to be brought forward in discussing the risks and benefits of treatment with the patient and the patient's relatives. Elderly comorbid patients may not survive to experience any benefit of a surgical intervention for this lethal disease.
The perioperative survival of 96% in the iTAA group and 71% in the rTAA group is comparable to that presented by others. von Allmen et al observed a 30-day survival of 94% and 70% after TEVAR for iTAA and rTAA, respectively, in their national analysis from England based on Hospital Episode Statistics. 5 A nationwide study from the United States comparing 364 cases of endovascular repair with 559 cases of open repair of ruptured descending aortic aneurysms reported 77% perioperative survival after TEVAR and 71% after open repair. 10 In the current study, there was no significant difference in 30-day survival or estimated long-term survival after TEVAR performed during the first and second half of the studied time period. However, the proportion of TAAs treated with TEVAR at our center has increased substantially during the study period, and it is highly likely that more cases that are complex were treated in the later time period, making a comparison difficult. Our reported 5-year survival of 63% after treatment of intact aneurysms can be compared with 54% in the national analysis from England, 60% in the Medtronic registries, and 62% in the Medicare population. 5, 7, 11 Data on outcome beyond the perioperative period after treatment of rTAA, however, are scarce. The current report indicates that mortality related to aortic rupture remains increased beyond 30 days after rTAA repair. Almost half of the patients were deceased within 90 days after rupture, and mortality increased to two-thirds at 3 years. The presence of deaths related to the operation beyond the 30-day postoperative period suggests that the 90-day survival rate may better represent procedure-related events in reporting results of TEVAR for TAA. In fact, based on particular 
Aorta related 3 (75) 3 (14) 11 (92) 3 (27)
GI, Gastrointestinal; iTAA, intact thoracic aortic aneurysm; rTAA, ruptured thoracic aortic aneurysm. scrutiny of the deaths within 90 days of TEVAR, we conclude that most of these were indeed late perioperative deaths. In contrast to evidence showing that late deaths after abdominal aortic aneurysm repair seldom are aorta related, 12 aorta-related deaths after the perioperative 30-day period were common in this study, 21% after treatment of iTAA compared with 9% in the Medtronic registries. 11 The majority of late deaths in the rTAA group were aorta related, which is consistent with a previous meta-analysis of endovascular vs open repair of ruptured descending aortic aneurysms, in which the results pointed to a considerable portion of late deaths after TEVAR being aneurysm related. 13 Aorta-related deaths can partly be explained by deaths occurring up to 90 days after repair that are an effect of the physiologic strains of the aortic rupture and the patient's comorbidity as well as by deaths occurring later because of aneurysms in other aortic segments, left untreated because of disease complexity, advanced age and comorbidity, and the patient's wish. This cohort study extends for a long time, particularly considering the development of endovascular aortic repair during the last years. The majority of the late aorta-related deaths happened during a time when there was no fenestrated or branched stent graft technology available. It is possible that modern endovascular technique, enabling treatment of multiple aortic segments, will improve long-term survival in this subset of patients with multiple and complex aneurysms. Aortic reinterventions are more common after endovascular repair of thoracic aneurysms than after open repair but have not been associated with a higher rate of aorta-related death. 5 One of the first studies investigating long-term results after TEVAR of TAAs reported a 5-year reintervention rate of 14%, 14 and our results of 13% after iTAA repair and 18% after rTAA repair indicate that the risk of aortic reintervention after TEVAR remains high. Interestingly, there were no aortic reinterventions performed later than 14 months after the primary procedure. Most reinterventions and aorta-related deaths occurred early during follow-up, which emphasizes the importance of early postoperative control imaging and surveillance after TEVAR of TAAs but indicates that this may be less necessary when the first postoperative year has passed. The cohort studied in this paper was treated at a tertiary referral center with extensive experience in treatment of thoracic aortic disease. The outcomes of TEVAR for dissections, transections, and mycotic aneurysms from the study center have previously been reported [15] [16] [17] and do not reflect the high mortality rate found in the rTAA cohort of the current study. This indicates that the high mortality in this cohort may rather be disease dependent than due to center-specific technical failures.
Others have performed studies on long-term outcomes of TEVAR, some of them with larger study populations. 18 An advantage with the current study is that the study population consists of patients with relatively homogeneous aneurysms all strictly confined to the thoracic aorta, excluding chronic dissection aneurysms as well as anastomotic pseudoaneurysms. In addition, the use of the unique PIN with the possibility of crossmatching data with the national population registry and cause of death registry offers the opportunity for 100% survival follow-up. A limitation of this study is that data regarding the discharge condition of the patients to independent living or nursing home are lacking. Instead, the analyses focused on survival, complications, and reinterventions as outcome parameters.
Because of the low incidence of thoracic aortic diseases, the study population of this single-center report is small, which is a limitation of the report and affects the possibility for multiple analyses of data. Owing to the high risk of death after rTAA, few patients remain at risk for analysis of long-term survival in this cohort. The data regarding long-term survival therefore need to be interpreted with caution. Nevertheless, we have opted to present long-term data as it is important to assess the outcome after rTAA repair in the presence of a high early mortality rate. Further analyses in larger multicenter or registry-based cohorts would be needed to confirm these findings.
CONCLUSIONS
In this study of long-term outcome after TEVAR for TAAs, survival was 63% at 5 years after iTAA repair, with a 13% reintervention rate. These results are comparable to those of previous reports on open and endovascular repair of iTAA. Results were more pessimistic after rTAA repair, however, for which two-thirds of the patients were deceased at 3 years of follow-up. Improved selection of patients to identify patients likely to truly benefit from rTAA repair with acceptable return to independent life would be beneficial. 
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